MedCity News » Stem Cell Treatment

Scientists are recognizing the power of transmogrifying cells to do their bidding. Heck, we recently found that heart cells can be reprogrammed into “pacemaker cells” through gene therapy....

https://medcitynews.com/2014/07/sqzbiotechs-cell-squeezing-better-way-reprogram-cells/

I have a confession to make . . . I’m only an intern at MedCity News. I just graduated high school and even though I’m young, I’ve already gotten a jump on my future as a journalist. Like m...

https://medcitynews.com/2014/07/young-healthcare-entrepreneurs-hit-ground-running-figuring-secret-success/

A wearable device that could transform how physicians diagnose the underlying causes of GI disorders is one of three innovative early stage life science companies Peter Thiel’s Breakout Labs is...

https://medcitynews.com/2014/06/breakout-labs-science-innovation-portfolio-adds-ekg-gut-stem-cells-treatment/

He’s only 15, but Intel International Science and Engineering Fair winner Nathan Han may be on his way to making some important advances in cancer research. His winning invention is a machine-l...

https://medcitynews.com/2014/05/intel-science-fair-winners-machine-learning-software-studying-cancer-genes/

In the latest stem cell innovation, a group of researchers from Stanford University successfully converted skin cells to stem cells to sperm cells, raising new questions about a potential path to...

https://medcitynews.com/2014/05/stem-cell-innovation-study-converts-skin-cells-sperm-cells-potential-infertility-treatment/

When you hear about blood shortages, that doesn’t just mean there’s a shortage of donated red blood cells. It could also mean platelets, a blood component that Sven Karlsson described as Band...

https://medcitynews.com/2014/04/biochip-mimcs-body-produces-platelets-address-challenges-platelet-transfusions/

While donation-based crowdfunding has taken some industries, like consumer technology, by storm, it’s been dismissed by some as a source of early-stage life science funding because of the sky-h...

https://medcitynews.com/2014/04/crowd-reacts-raise-233k-clinical-trials-stem-cell-therapy-multiple-sclerosis/

By William T. Koustas – The litigation between Regenerative Sciences, LLC (“Regenerative”) and FDA may have come to an end on Tuesday, February 4th, when the United States Court of Appeals ...

https://medcitynews.com/2014/02/d-c-circuit-rules-fda-can-regulate-autologous-stem-cells/

Remember mini-brains? The human body and pharma benefit from stem cells and miniaturization again with the advent of this life sciences innovation: ‘mini kidneys.’ Though scientists have grow...

https://medcitynews.com/2013/11/scientists-generate-first-mini-kidneys-human-stem-cells/

While Medtronic (MDT) is at work to launch its new artificial pancreas system, researchers at the University of Copenhagen have come up with a new 3-D method with potential to create mini human p...

https://medcitynews.com/2013/10/scientists-grow-3-d-mini-artificial-pancreas-using-aim-fight-diabetes/

We can now grow complex human brain tissue in a test tube. Scientists in Vienna, Austria, used a method that allows pluripotent stem cells to develop into mini-brains (i.e., cerebral organoids) t...

https://medcitynews.com/2013/08/hold-onto-your-hats-pharma-scientists-grow-3-d-mini-brains-successfully/

Thanks in part to a SBIR Fast Track grant worth up to $2.8 million, stem cell company Athersys (Nasdaq: ATHX) is gearing up to advance its third MultiStem program into Phase 2 clinical trials. Cl...

https://medcitynews.com/2013/08/stem-cell-firm-athersys-faces-enrollment-struggles-with-one-phase-2-study-readies-to-begin-another/

If you think you’ve heard about all the cool regenerative medicine uses for stem cells, think again. A group of researchers from Guangzhou Institutes of Biomedicine and Health in China have use...

https://medcitynews.com/2013/08/wow-of-the-week-scientists-make-teeth-from-human-urine-in-latest-test-of-stem-cell-tech/

StemBioSys, a San Antonio company that manufactures and develops stem cell technologies in the regenerative medicine field, has landed $2,377,802. It still seeks $5,622,198, according to the reg...

https://medcitynews.com/2013/07/texas-stem-cell-tech-company-raises-2-3-million-seeks-5-6-more/

Apparently, there are still some Twitter holdouts in the science world. Ben Paylor writes on the Signals Blog: A recent piece in Regenerative Medicine by Lee Buckler argues that social media is s...

https://medcitynews.com/2013/04/no-frivolity-here-15-stem-cell-experts-and-10-news-sources-to-follow-on-twitter/

Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means s...

https://medcitynews.com/2013/03/stem-cell-company-athersys-expects-more-rd-spending-potential-partnerships-in-2013/

A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 mill...

https://medcitynews.com/2013/02/texas-biotech-rounds-up-2-million-for-platform-to-grow-stem-cells-faster/

If you are having a hard time choosing between President Barack Obama and Republican nominee Gov. Mitt Romney, here are some weekend reading assignments for you. Whether you’re interested in st...

https://medcitynews.com/2012/11/still-undecided-let-google-techpresident-and-aarp-help/

It’s easy to look at Nobel Prize winners and assume the greatness of their work. But it’s even more awe-inspiring to understand the research and see it in action. This year, the Nobel Prize i...

https://medcitynews.com/2012/10/how-one-company-is-using-nobel-prize-winning-stem-cell-research-to-develop-better-drugs/

A California regenerative medicine firm raised $9.2 million and is planning new clinical trials for its stem cell modulator in patients with blood cancer. Read more. The post Maker of stem cell...

https://medcitynews.com/2012/09/maker-of-stem-cell-modulators-brings-in-9-2-million-for-blood-cancer-trials/

A cure for spinal cord injury? Diabetes? Macular degeneration? Hope or just hype? There are now some clinical trials using embryonic stem cells to treat serious diseases for which no other good t...

https://medcitynews.com/2012/08/medical-megatrends-stem-cells-part-iii/

UPDATED Under the umbrella of regenerative medicine, cell therapies are the foundation of many of the companies developing the next wave of drugs for diseases of the nervous system, cancer, cardi...

https://medcitynews.com/2012/08/cell-therapy-research-startup-awarded-350k-from-paypal-co-creators-foundation/

Imagine a man with a recent severe heart attack who has the muscle repaired with stem cells or a child with a severe bladder defect repaired with stem cells grown on a biodegradable scaffold. Sou...

https://medcitynews.com/2012/07/medical-megatrends-stem-cells-part-ii-of-iii/

New cells to replace those destroyed in diabetes type 1, cells to help heal a heart attack, cells to cure leukemia — this is the promise of stem cells. Some of this is happening now; more will ...

https://medcitynews.com/2012/07/medical-megatrends-stems-cells-part-i-of-iii/

A company’s new technique to improve female infertility treatment based on the controversial idea that women aren’t in fact born with a finite number of eggs is getting the attention of inves...

https://medcitynews.com/2012/07/investors-back-female-fertility-treatment-that-may-re-energize-eggs-using-stem-cells/

The regenerative medicine company Juventas Therapeutics, which had already said it added Takeda Pharmaceuticals to its roster of investors, said this weekend it has raised enough money to take it...

https://medcitynews.com/2012/07/new-stem-cell-treatment-for-ischemia-heart-failure-raises-enough-for-clinical-trials/

Regenerative medicine wound healing company SironRX Therapeutics has hired a first-time CEO as its first-ever, full-time CEO. Evan Facher most recently worked as general manager of Pittsburgh int...

https://medcitynews.com/2012/05/wound-healing-startup-sironrx-hires-new-ceo-gets-ok-on-clinical-trial/

It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any sales, but Athersys (NASDAQ:A...

https://medcitynews.com/2012/05/why-is-athersys-suddenly-hyping-its-preclinical-obesity-drug/

When regenerative medicine firm Cytomedix (OTC:CMXI) acquired biotechnology company Aldagen, the stem cell-based stroke treatment in clinical trials was the centerpiece of the all stock deal. Cyt...

https://medcitynews.com/2012/05/two-stem-cell-therapies-from-cytomedix-to-start-trials-stroke-study-expands/

Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients. The Cleveland-based company, which recently secured an important i...

https://medcitynews.com/2012/05/regenerative-medicine-company-begins-enrollment-in-critical-limb-ischemia-trial/